Back to top

Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?

Read MoreHide Full Article

Investors focused on the Medical space have likely heard of Amedisys (AMED - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Amedisys is a member of the Medical sector. This group includes 838 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. AMED is currently sporting a Zacks Rank of #1 (Strong Buy).

Within the past quarter, the Zacks Consensus Estimate for AMED's full-year earnings has moved 5.60% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

Our latest available data shows that AMED has returned about 115.35% since the start of the calendar year. In comparison, Medical companies have returned an average of -5.70%. As we can see, Amedisys is performing better than its sector in the calendar year.

Looking more specifically, AMED belongs to the Medical - Outpatient and Home Healthcare industry, which includes 17 individual stocks and currently sits at #97 in the Zacks Industry Rank. On average, stocks in this group have lost 13.07% this year, meaning that AMED is performing better in terms of year-to-date returns.

Investors with an interest in Medical stocks should continue to track AMED. The stock will be looking to continue its solid performance.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Amedisys, Inc. (AMED) - free report >>

More from Zacks Tale of the Tape

You May Like

Published in